Skip to main content
. Author manuscript; available in PMC: 2012 Feb 8.
Published in final edited form as: Psychol Med. 2010 Apr 12;41(1):151–162. doi: 10.1017/S0033291710000553

Table 2.

Significant Predictors and Moderators of Remission with Monotherapy by 12 Weeks of Treatments: Results from Cox Survival Regression Models

HR (95% CI)
Main effect Interaction with treatment Interaction with site Interaction with treatment and site
PAS-SR
Panic symptoms .76 (.63–.92)
Drug phobia .79 (.64–.96)
Fear of losing control/depersonalization .75 (.63–.91)
Agoraphobia .82 (.68–1.00)
Medical reassurance .59(.39–.91) 2.35 (1.00–5.51)
Loss sensitivity 2.29 (1.08–4.86)
Separation anxiety 2.33 (1.09–5.01)
MOODS-SR (depressive component)
Depressive mood .74 (.62–.89)
Suicidality .77 (.64–.93)
Psychomotor retardation .69 (.58–.82)
Neurovegetative symptoms .84 (.70–1.00)
Psychotic features .82 (.68–.98)
MOODS-SR (manic/hypomania component)
Psychomotor activation .70 (.49–1.00)
Total SHY .76 (.63–.91)
Baseline HDRS-17 .74 (.61–.91)
Baseline HDRS-25 .68 (.56–.83)
Marital status (married) 1.69 (1.19–2.39)
WSAS .56 (.46–.68)
Hypersomnia HDRS .65 (.52–.81) 2.58 (1.64−4.07)
Any anxiety disorder .69 (.48–.99)
HHS Vulnerability Disclosure